BAXTER INTERNATIONAL INC (BAX) Stock Fundamental Analysis

NYSE:BAX • US0718131099

19.575 USD
-0.8 (-3.9%)
Last: Mar 2, 2026, 01:35 PM
Fundamental Rating

3

Taking everything into account, BAX scores 3 out of 10 in our fundamental rating. BAX was compared to 184 industry peers in the Health Care Equipment & Supplies industry. BAX may be in some trouble as it scores bad on both profitability and health. BAX has a valuation in line with the averages, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • BAX had positive earnings in the past year.
  • In the past year BAX had a positive cash flow from operations.
  • In multiple years BAX reported negative net income over the last 5 years.
  • Of the past 5 years BAX 4 years had a positive operating cash flow.
BAX Yearly Net Income VS EBIT VS OCF VS FCFBAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B -2B 4B

1.2 Ratios

  • BAX has a Return On Assets of -1.62%. This is in the better half of the industry: BAX outperforms 70.65% of its industry peers.
  • BAX's Return On Equity of -4.71% is fine compared to the rest of the industry. BAX outperforms 70.65% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 3.05%, BAX is in the better half of the industry, outperforming 70.65% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for BAX is significantly below the industry average of 8.97%.
Industry RankSector Rank
ROA -1.62%
ROE -4.71%
ROIC 3.05%
ROA(3y)-0.58%
ROA(5y)1.52%
ROE(3y)-6.47%
ROE(5y)1.48%
ROIC(3y)3.5%
ROIC(5y)4.71%
BAX Yearly ROA, ROE, ROICBAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

1.3 Margins

  • BAX has a Operating Margin of 6.40%. This is in the better half of the industry: BAX outperforms 71.20% of its industry peers.
  • BAX's Operating Margin has declined in the last couple of years.
  • With a Gross Margin value of 35.05%, BAX is not doing good in the industry: 73.37% of the companies in the same industry are doing better.
  • BAX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 6.4%
PM (TTM) N/A
GM 35.05%
OM growth 3Y-19.11%
OM growth 5Y-13.17%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.94%
GM growth 5Y-2.16%
BAX Yearly Profit, Operating, Gross MarginsBAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BAX is destroying value.
  • There is no outstanding debt for BAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BAX Yearly Shares OutstandingBAX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M
BAX Yearly Total Debt VS Total AssetsBAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • BAX has an Altman-Z score of 2.25. This is not the best score and indicates that BAX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.25, BAX is doing good in the industry, outperforming 63.59% of the companies in the same industry.
  • The Debt to FCF ratio of BAX is 38.94, which is on the high side as it means it would take BAX, 38.94 years of fcf income to pay off all of its debts.
  • BAX has a better Debt to FCF ratio (38.94) than 67.39% of its industry peers.
  • BAX has a Debt/Equity ratio of 1.21. This is a high value indicating a heavy dependency on external financing.
  • BAX's Debt to Equity ratio of 1.21 is on the low side compared to the rest of the industry. BAX is outperformed by 77.17% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF 38.94
Altman-Z 2.25
ROIC/WACC0.41
WACC7.51%
BAX Yearly LT Debt VS Equity VS FCFBAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

  • BAX has a Current Ratio of 1.84. This is a normal value and indicates that BAX is financially healthy and should not expect problems in meeting its short term obligations.
  • BAX's Current ratio of 1.84 is on the low side compared to the rest of the industry. BAX is outperformed by 66.30% of its industry peers.
  • BAX has a Quick Ratio of 1.18. This is a normal value and indicates that BAX is financially healthy and should not expect problems in meeting its short term obligations.
  • BAX's Quick ratio of 1.18 is on the low side compared to the rest of the industry. BAX is outperformed by 68.48% of its industry peers.
Industry RankSector Rank
Current Ratio 1.84
Quick Ratio 1.18
BAX Yearly Current Assets VS Current LiabilitesBAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2

3. Growth

3.1 Past

  • BAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.24%.
  • BAX shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -5.98% yearly.
EPS 1Y (TTM)-16.24%
EPS 3Y-13.44%
EPS 5Y-5.98%
EPS Q2Q%-24.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%8.03%

3.2 Future

  • BAX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.95% yearly.
  • BAX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.22% yearly.
EPS Next Y-0.01%
EPS Next 2Y3.92%
EPS Next 3Y5.38%
EPS Next 5Y6.95%
Revenue Next Year2.3%
Revenue Next 2Y2.29%
Revenue Next 3Y2.36%
Revenue Next 5Y2.22%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
BAX Yearly Revenue VS EstimatesBAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 5B 10B 15B
BAX Yearly EPS VS EstimatesBAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3

6

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 8.62, the valuation of BAX can be described as reasonable.
  • Compared to the rest of the industry, the Price/Earnings ratio of BAX indicates a rather cheap valuation: BAX is cheaper than 96.74% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.07, BAX is valued rather cheaply.
  • BAX is valuated reasonably with a Price/Forward Earnings ratio of 8.62.
  • BAX's Price/Forward Earnings ratio is rather cheap when compared to the industry. BAX is cheaper than 96.20% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of BAX to the average of the S&P500 Index (28.05), we can say BAX is valued rather cheaply.
Industry RankSector Rank
PE 8.62
Fwd PE 8.62
BAX Price Earnings VS Forward Price EarningsBAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BAX is valued cheaply inside the industry as 91.85% of the companies are valued more expensively.
  • BAX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BAX is cheaper than 74.46% of the companies in the same industry.
Industry RankSector Rank
P/FCF 41.24
EV/EBITDA 10.78
BAX Per share dataBAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.92%
EPS Next 3Y5.38%

4

5. Dividend

5.1 Amount

  • BAX has a yearly dividend return of 0.20%, which is pretty low.
  • BAX's Dividend Yield is rather good when compared to the industry average which is at 0.20. BAX pays more dividend than 90.22% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, BAX's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.2%

5.2 History

  • On average, the dividend of BAX grows each year by 6.89%, which is quite nice.
  • BAX has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)6.89%
Div Incr Years0
Div Non Decr Years0
BAX Yearly Dividends per shareBAX Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • The earnings of BAX are negative and hence is the payout ratio. BAX will probably not be able to sustain this dividend level.
  • The dividend of BAX is growing around the same rate as the earnings are growing. If this keeps up the dividend growth is sustainable.
DP-119.65%
EPS Next 2Y3.92%
EPS Next 3Y5.38%
BAX Yearly Income VS Free CF VS DividendBAX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B -2B 4B

BAXTER INTERNATIONAL INC

NYSE:BAX (3/2/2026, 1:35:10 PM)

19.575

-0.8 (-3.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-12
Earnings (Next)04-29
Inst Owners102.74%
Inst Owner Change7.02%
Ins Owners0.28%
Ins Owner Change11.63%
Market Cap10.06B
Revenue(TTM)N/A
Net Income(TTM)-341.00M
Analysts55.2
Price Target22.21 (13.46%)
Short Float %6.95%
Short Ratio3.89
Dividend
Industry RankSector Rank
Dividend Yield 0.2%
Yearly Dividend1.16
Dividend Growth(5Y)6.89%
DP-119.65%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-27
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.96%
Min EPS beat(2)-4.25%
Max EPS beat(2)14.16%
EPS beat(4)3
Avg EPS beat(4)8.34%
Min EPS beat(4)-4.25%
Max EPS beat(4)14.16%
EPS beat(8)7
Avg EPS beat(8)5.47%
EPS beat(12)9
Avg EPS beat(12)3.78%
EPS beat(16)11
Avg EPS beat(16)3.66%
Revenue beat(2)0
Avg Revenue beat(2)-1.91%
Min Revenue beat(2)-2.38%
Max Revenue beat(2)-1.44%
Revenue beat(4)2
Avg Revenue beat(4)-0.36%
Min Revenue beat(4)-2.38%
Max Revenue beat(4)1.93%
Revenue beat(8)5
Avg Revenue beat(8)-0.06%
Revenue beat(12)6
Avg Revenue beat(12)-0.48%
Revenue beat(16)6
Avg Revenue beat(16)-2.41%
PT rev (1m)-6.44%
PT rev (3m)-12.66%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.52%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)-0.45%
Valuation
Industry RankSector Rank
PE 8.62
Fwd PE 8.62
P/S 0.91
P/FCF 41.24
P/OCF 13.43
P/B 1.39
P/tB N/A
EV/EBITDA 10.78
EPS(TTM)2.27
EY11.6%
EPS(NY)2.27
Fwd EY11.59%
FCF(TTM)0.47
FCFY2.42%
OCF(TTM)1.46
OCFY7.44%
SpS21.44
BVpS14.09
TBVpS-5.77
PEG (NY)N/A
PEG (5Y)N/A
Graham Number26.82
Profitability
Industry RankSector Rank
ROA -1.62%
ROE -4.71%
ROCE 4.08%
ROIC 3.05%
ROICexc 3.39%
ROICexgc 9.84%
OM 6.4%
PM (TTM) N/A
GM 35.05%
FCFM 2.21%
ROA(3y)-0.58%
ROA(5y)1.52%
ROE(3y)-6.47%
ROE(5y)1.48%
ROIC(3y)3.5%
ROIC(5y)4.71%
ROICexc(3y)3.9%
ROICexc(5y)5.53%
ROICexgc(3y)10.35%
ROICexgc(5y)12.85%
ROCE(3y)4.85%
ROCE(5y)6.42%
ROICexgc growth 3Y-24.28%
ROICexgc growth 5Y-17.95%
ROICexc growth 3Y-15.78%
ROICexc growth 5Y-22.54%
OM growth 3Y-19.11%
OM growth 5Y-13.17%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.94%
GM growth 5Y-2.16%
F-Score3
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 1.21
Debt/FCF 38.94
Debt/EBITDA 5.17
Cap/Depr 51.22%
Cap/Sales 4.58%
Interest Coverage 250
Cash Conversion 44.27%
Profit Quality N/A
Current Ratio 1.84
Quick Ratio 1.18
Altman-Z 2.25
F-Score3
WACC7.51%
ROIC/WACC0.41
Cap/Depr(3y)49.31%
Cap/Depr(5y)63.51%
Cap/Sales(3y)5.12%
Cap/Sales(5y)5.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.24%
EPS 3Y-13.44%
EPS 5Y-5.98%
EPS Q2Q%-24.14%
EPS Next Y-0.01%
EPS Next 2Y3.92%
EPS Next 3Y5.38%
EPS Next 5Y6.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%8.03%
Revenue Next Year2.3%
Revenue Next 2Y2.29%
Revenue Next 3Y2.36%
Revenue Next 5Y2.22%
EBIT growth 1Y-43.57%
EBIT growth 3Y-23.92%
EBIT growth 5Y-14.31%
EBIT Next Year53.79%
EBIT Next 3Y15.53%
EBIT Next 5Y17.33%
FCF growth 1Y-73.82%
FCF growth 3Y-27.1%
FCF growth 5Y-16.46%
OCF growth 1Y-54.16%
OCF growth 3Y-22.88%
OCF growth 5Y-13.5%

BAXTER INTERNATIONAL INC / BAX FAQ

What is the fundamental rating for BAX stock?

ChartMill assigns a fundamental rating of 3 / 10 to BAX.


Can you provide the valuation status for BAXTER INTERNATIONAL INC?

ChartMill assigns a valuation rating of 6 / 10 to BAXTER INTERNATIONAL INC (BAX). This can be considered as Fairly Valued.


What is the profitability of BAX stock?

BAXTER INTERNATIONAL INC (BAX) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for BAX stock?

The Earnings per Share (EPS) of BAXTER INTERNATIONAL INC (BAX) is expected to decline by -0.01% in the next year.


How sustainable is the dividend of BAXTER INTERNATIONAL INC (BAX) stock?

The dividend rating of BAXTER INTERNATIONAL INC (BAX) is 4 / 10 and the dividend payout ratio is -119.65%.